Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:27:27.669Z.
Consensus retrieved: 2026-10-06T13:24:38.276Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:27:27.669Z.
Quote observation: 2026-10-06T16:25:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d8f500f051b8c2f6d9df2326c38ce0bcf8edb39987555b97daf7c0f1a95d0fd4
Forward PE Ratio (N/A) = Dated Quote Price ($3.77) / Consensus Forward EPS ($-4.18)
FORWARD PE RATIO
N/A
LENZ Therapeutics, Inc.
Market Cap
$118.05M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | $118.05M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.03M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $116.83M | N/A |
| Genelux Corporation (GNLX)vs › | $116.80M | N/A |
| BGM Group Ltd. (BGM)vs › | $116.34M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.84M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.73M | N/A |
| Seer, Inc. (SEER)vs › | $121.76M | N/A |
| Cibus, Inc. (CBUS)vs › | $122.13M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $122.29M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $3.77, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-4.18 | $-4.45 – $-3.83 | 5 | n/m |
| 2027-12-31 | $-2.72 | $-3.67 – $-2.02 | 5 | n/m |
| 2028-12-31 | $-1.17 | $-2.04 – $-0.18 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
